This implies that inflammatory lymphangiogenesis may have pleiotropic effects at different stages of IBD and that VEGF-C exhibits a dual effect in inflammation, making it an important therapeutic target for IBD. This evidence concerns the gene VEGFC and inflammatory bowel disease.